Targeting Nonclassical Oncogenes for Therapy in T-ALL

Cancer Cell

Volumn 21, Issue 4, 2012, Pages 459-472

  Subramaniam, Prem S ^a   Whye, Dosh W ^a   Efimenko, Evgeni ^a   Chen, Jianchung ^a   Tosello, Valeria ^b   De Keersmaecker, Kim ^b   Kashishian, Adam ^c,d   Thompson, Mary Ann ^e   Castillo, Mireia ^f   Cordon Cardo, Carlos ^f   Davé, Utpal P ^e   Ferrando, Adolfo ^a,b   Lannutti, Brian J ^c,d   Diacovo, Thomas G ^a  

^a Department of Medicine   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c Calistoga Pharmaceuticals   (United States)

^d Gilead Sciences   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; ANTINEOPLASTIC AGENT; CAL 130; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE DELTA; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; LEUKEMOGENESIS; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT;

MUS;

EID: 84859807614     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2012.02.029     Document Type: Article

References (61)

1. Armstrong F., Brunet de la Grange P., Gerby B., Rouyez M.C., Calvo J., Fontenay M., Boissel N., Dombret H., Baruchel A., Landman-Parker J., et al. NOTCH is a key regulator of human T-cell acute leukemia initiating cell activity. Blood 2009, 113:1730-1740.
2. Ayala F., Dewar R., Kieran M., Kalluri R. Contribution of bone microenvironment to leukemogenesis and leukemia progression. Leukemia 2009, 23:2233-2241.
3. Beesley A.H., Firth M.J., Ford J., Weller R.E., Freitas J.R., Perera K.U., Kees U.R. Glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia is associated with a proliferative metabolism. Br. J. Cancer 2009, 100:1926-1936.
4. Bernard O., Larsen C.J., Hampe A., Mauchauffé M., Berger R., Mathieu-Mahul D. Molecular mechanisms of a t(8;14)(q24;q11) translocation juxtaposing c-myc and TcR-alpha genes in a T-cell leukaemia: involvement of a V alpha internal heptamer. Oncogene 1988, 2:195-200.
5. Burger J.A., Ghia P., Rosenwald A., Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009, 114:3367-3375.
6. Cantley L.C. The phosphoinositide 3-kinase pathway. Science 2002, 296:1655-1657.
7. Carnero A., Blanco-Aparicio C., Renner O., Link W., Leal J.F. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr. Cancer Drug Targets 2008, 8:187-198.
8. Cohen P., Frame S. The renaissance of GSK3. Nat. Rev. Mol. Cell Biol. 2001, 2:769-776.
9. Collazo M.M., Wood D., Paraiso K.H., Lund E., Engelman R.W., Le C.T., Stauch D., Kotsch K., Kerr W.G. SHIP limits immunoregulatory capacity in the T-cell compartment. Blood 2009, 113:2934-2944.
10. Crouthamel M.C., Kahana J.A., Korenchuk S., Zhang S.Y., Sundaresan G., Eberwein D.J., Brown K.K., Kumar R. Mechanism and management of AKT inhibitor-induced hyperglycemia. Clin. Cancer Res. 2009, 15:217-225.
11. Duronio V. The life of a cell: apoptosis regulation by the PI3K/PKB pathway. Biochem. J. 2008, 415:333-344.
12. Erlacher M., Michalak E.M., Kelly P.N., Labi V., Niederegger H., Coultas L., Adams J.M., Strasser A., Villunger A. BH3-only proteins Puma and Bim are rate-limiting for gamma-radiation- and glucocorticoid-induced apoptosis of lymphoid cells in vivo. Blood 2005, 106:4131-4138.
13. Fabian M.A., Biggs W.H., Treiber D.K., Atteridge C.E., Azimioara M.D., Benedetti M.G., Carter T.A., Ciceri P., Edeen P.T., Floyd M., et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 2005, 23:329-336.
14. Finger L.R., Harvey R.C., Moore R.C., Showe L.C., Croce C.M. A common mechanism of chromosomal translocation in T- and B-cell neoplasia. Science 1986, 234:982-985.
15. Finlay D.K., Sinclair L.V., Feijoo C., Waugh C.M., Hagenbeek T.J., Spits H., Cantrell D.A. Phosphoinositide-dependent kinase 1 controls migration and malignant transformation but not cell growth and proliferation in PTEN-null lymphocytes. J. Exp. Med. 2009, 206:2441-2454.
16. Foukas L.C., Berenjeno I.M., Gray A., Khwaja A., Vanhaesebroeck B. Activity of any class IA PI3K isoform can sustain cell proliferation and survival. Proc. Natl. Acad. Sci. USA 2010, 107:11381-11386.
17. Guo W., Lasky J.L., Chang C.J., Mosessian S., Lewis X., Xiao Y., Yeh J.E., Chen J.Y., Iruela-Arispe M.L., Varella-Garcia M., Wu H. Multi-genetic events collaboratively contribute to Pten-null leukaemia stem-cell formation. Nature 2008, 453:529-533.
18. Guo W., Schubbert S., Chen J.Y., Valamehr B., Mosessian S., Shi H., Dang N.H., Garcia C., Theodoro M.F., Varella-Garcia M., Wu H. Suppression of leukemia development caused by PTEN loss. Proc. Natl. Acad. Sci. USA 2011, 108:1409-1414.
19. Gutierrez A., Sanda T., Grebliunaite R., Carracedo A., Salmena L., Ahn Y., Dahlberg S., Neuberg D., Moreau L.A., Winter S.S., et al. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood 2009, 114:647-650.
20. Hagenbeek T.J., Spits H. T-cell lymphomas in T-cell-specific Pten-deficient mice originate in the thymus. Leukemia 2008, 22:608-619.
21. Hagenbeek T.J., Naspetti M., Malergue F., Garçon F., Nunès J.A., Cleutjens K.B., Trapman J., Krimpenfort P., Spits H. The loss of PTEN allows TCR alphabeta lineage thymocytes to bypass IL-7 and Pre-TCR-mediated signaling. J. Exp. Med. 2004, 200:883-894.
22. Hennet T., Hagen F.K., Tabak L.A., Marth J.D. T-cell-specific deletion of a polypeptide N-acetylgalactosaminyl-transferase gene by site-directed recombination. Proc. Natl. Acad. Sci. USA 1995, 92:12070-12074.
23. Hickey F.B., Cotter T.G. BCR-ABL regulates phosphatidylinositol 3-kinase-p110gamma transcription and activation and is required for proliferation and drug resistance. J. Biol. Chem. 2006, 281:2441-2450.
24. Hinton H.J., Alessi D.R., Cantrell D.A. The serine kinase phosphoinositide-dependent kinase 1 (PDK1) regulates T cell development. Nat. Immunol. 2004, 5:539-545.
25. Hoellenriegel J., Meadows S.A., Sivina M., Wierda W.G., Kantarjian H., Keating M.J., Giese N., O'Brien S., Yu A., Miller L.L., et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011, 118:3603-3612.
26. Huang W.C., Hung M.C. Induction of Akt activity by chemotherapy confers acquired resistance. J. Formos. Med. Assoc. 2009, 108:180-194.
27. Jackson S.P., Schoenwaelder S.M., Goncalves I., Nesbitt W.S., Yap C.L., Wright C.E., Kenche V., Anderson K.E., Dopheide S.M., Yuan Y., et al. PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat. Med. 2005, 11:507-514.
28. Ji H., Rintelen F., Waltzinger C., Bertschy Meier D., Bilancio A., Pearce W., Hirsch E., Wymann M.P., Rückle T., Camps M., et al. Inactivation of PI3Kgamma and PI3Kdelta distorts T-cell development and causes multiple organ inflammation. Blood 2007, 110:2940-2947.
29. Jia S., Liu Z., Zhang S., Liu P., Zhang L., Lee S.H., Zhang J., Signoretti S., Loda M., Roberts T.M., Zhao J.J. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 2008, 454:776-779.
30. Jotta P.Y., Ganazza M.A., Silva A., Viana M.B., da Silva M.J., Zambaldi L.J., Barata J.T., Brandalise S.R., Yunes J.A. Negative prognostic impact of PTEN mutation in pediatric T-cell acute lymphoblastic leukemia. Leukemia 2010, 24:239-242.
31. Kang S., Denley A., Vanhaesebroeck B., Vogt P.K. Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc. Natl. Acad. Sci. USA 2006, 103:1289-1294.
32. Karaman M.W., Herrgard S., Treiber D.K., Gallant P., Atteridge C.E., Campbell B.T., Chan K.W., Ciceri P., Davis M.I., Edeen P.T., et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 2008, 26:127-132.
33. Katso R., Okkenhaug K., Ahmadi K., White S., Timms J., Waterfield M.D. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu. Rev. Cell Dev. Biol. 2001, 17:615-675.
34. Konopleva M., Tabe Y., Zeng Z., Andreeff M. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. Drug Resist. Updat. 2009, 12:103-113.
35. Larson Gedman A., Chen Q., Kugel Desmoulin S., Ge Y., LaFiura K., Haska C.L., Cherian C., Devidas M., Linda S.B., Taub J.W., Matherly L.H. The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Leukemia 2009, 23:1417-1425.
36. Liu X., Karnell J.L., Yin B., Zhang R., Zhang J., Li P., Choi Y., Maltzman J.S., Pear W.S., Bassing C.H., Turka L.A. Distinct roles for PTEN in prevention of T cell lymphoma and autoimmunity in mice. J. Clin. Invest. 2010, 120:2497-2507.
37. Lo T.C., Barnhill L.M., Kim Y., Nakae E.A., Yu A.L., Diccianni M.B. Inactivation of SHIP1 in T-cell acute lymphoblastic leukemia due to mutation and extensive alternative splicing. Leuk. Res. 2009, 33:1562-1566.
38. Maser R.S., Choudhury B., Campbell P.J., Feng B., Wong K.K., Protopopov A., O'Neil J., Gutierrez A., Ivanova E., Perna I., et al. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature 2007, 447:966-971.
39. Okkenhaug K., Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat. Rev. Immunol. 2003, 3:317-330.
40. Palomero T., Dominguez M., Ferrando A.A. The role of the PTEN/AKT Pathway in NOTCH1-induced leukemia. Cell Cycle 2008, 7:965-970.
41. Puri K.D., Doggett T.A., Douangpanya J., Hou Y., Tino W.T., Wilson T., Graf T., Clayton E., Turner M., Hayflick J.S., Diacovo T.G. Mechanisms and implications of phosphoinositide 3-kinase δ in promoting neutrophil trafficking into inflamed tissue. Blood 2004, 103:3448-3456.
42. Sadhu C., Masinovsky B., Dick K., Sowell C.G., Staunton D.E. Essential role of phosphoinositide 3-kinase δ in neutrophil directional movement. J. Immunol. 2003, 170:2647-2654.
43. Safran M., Kim W.Y., Kung A.L., Horner J.W., DePinho R.A., Kaelin W.G. Mouse reporter strain for noninvasive bioluminescent imaging of cells that have undergone Cre-mediated recombination. Mol. Imaging 2003, 2:297-302.
44. Salmena L., Carracedo A., Pandolfi P.P. Tenets of PTEN tumor suppression. Cell 2008, 133:403-414.
45. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., Gazdar A., Powell S.M., Riggins G.J., et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304:554.
46. Schmelzle T., Hall M.N. TOR, a central controller of cell growth. Cell 2000, 103:253-262.
47. Silva A., Yunes J.A., Cardoso B.A., Martins L.R., Jotta P.Y., Abecasis M., Nowill A.E., Leslie N.R., Cardoso A.A., Barata J.T. PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J. Clin. Invest. 2008, 118:3762-3774.
48. Sopasakis V.R., Liu P., Suzuki R., Kondo T., Winnay J., Tran T.T., Asano T., Smyth G., Sajan M.P., Farese R.V., et al. Specific roles of the p110alpha isoform of phosphatidylinsositol 3-kinase in hepatic insulin signaling and metabolic regulation. Cell Metab. 2010, 11:220-230.
49. Strasser A., Puthalakath H., Bouillet P., Huang D.C., O'Connor L., O'Reilly L.A., Cullen L., Cory S., Adams J.M. The role of bim, a proapoptotic BH3-only member of the Bcl-2 family in cell-death control. Ann. N Y Acad. Sci. 2000, 917:541-548.
50. Sujobert P., Bardet V., Cornillet-Lefebvre P., Hayflick J.S., Prie N., Verdier F., Vanhaesebroeck B., Muller O., Pesce F., Ifrah N., et al. Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 2005, 106:1063-1066.
51. Sulis M.L., Parsons R. PTEN: from pathology to biology. Trends Cell Biol. 2003, 13:478-483.
52. Suzuki A., Yamaguchi M.T., Ohteki T., Sasaki T., Kaisho T., Kimura Y., Yoshida R., Wakeham A., Higuchi T., Fukumoto M., et al. T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 2001, 14:523-534.
53. Swat W., Montgrain V., Doggett T.A., Douangpanya J., Puri K., Vermi W., Diacovo T.G. Essential role of PI3Kdelta and PI3Kgamma in thymocyte survival. Blood 2006, 107:2415-2422.
54. Tarasenko T., Kole H.K., Chi A.W., Mentink-Kane M.M., Wynn T.A., Bolland S. T cell-specific deletion of the inositol phosphatase SHIP reveals its role in regulating Th1/Th2 and cytotoxic responses. Proc. Natl. Acad. Sci. USA 2007, 104:11382-11387.
55. Trotman L.C., Niki M., Dotan Z.A., Koutcher J.A., Di Cristofano A., Xiao A., Khoo A.S., Roy-Burman P., Greenberg N.M., Van Dyke T., et al. Pten dose dictates cancer progression in the prostate. PLoS Biol. 2003, 1:E59.
56. Wang Z., Malone M.H., He H., McColl K.S., Distelhorst C.W. Microarray analysis uncovers the induction of the proapoptotic BH3-only protein Bim in multiple models of glucocorticoid-induced apoptosis. J. Biol. Chem. 2003, 278:23861-23867.
57. Webb L.M., Vigorito E., Wymann M.P., Hirsch E., Turner M.J. Cutting edge: T cell development requires the combined activities of the p110gamma and p110delta catalytic isoforms of phosphatidylinositol 3-kinase. J. Immunol. 2005, 175:2783-2787.
58. Wee S., Wiederschain D., Maira S.M., Loo A., Miller C., deBeaumont R., Stegmeier F., Yao Y.M., Lengauer C. PTEN-deficient cancers depend on PIK3CB. Proc. Natl. Acad. Sci. USA 2008, 105:13057-13062.
59. Yuan T.L., Cantley L.C. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008, 27:5497-5510.
60. Zhao L., Vogt P.K. Class I PI3K in oncogenic cellular transformation. Oncogene 2008, 27:5486-5496.
61. Zunder E.R., Knight Z.A., Houseman B.T., Apsel B., Shokat K.M. Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha. Cancer Cell 2008, 14:180-192.